John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a condition that can lead to kidney failure.

By Barbara J. Toman • August 16, 2022

John Lieske, M.D., discusses Mayo Clinic Laboratories' urinary ammonium testing. A test that takes the guesswork out of determining acid base disorders by giving nephrologists a true understanding of a patient’s true urinary ammonium level.

By Cory Pedersen • March 15, 2022

Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and insight on disease expression.

By Samantha Rossi • June 15, 2021

A collaborative study between Mayo Clinic and the University of Illinois debunked the previous consensus about how kidney stones grow.

By Chris J. Bahnsen • June 1, 2021

Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.

By Chris J. Bahnsen • June 1, 2021

This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for May include the following sub-specialties: Bone and Soft Tissue & Infectious Disease, Gynecological, Placental, and Renal.

By MCL Education • May 12, 2020

This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. This case sub-specialty is Renal.

By MCL Education • May 12, 2020

Mayo Clinic researchers are tracking the familiar characteristics of kidney stone formers in an online prediction tool that could help sufferers anticipate if they'll experience future episodes.

By Mayo Clinic News Network • February 5, 2019

John Lieske, M.D., gives an overview of the phospholipase A2 receptor antibodies testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • January 18, 2019

There have been concerns in the U.S. recently about the possible harmful side effects from absorbing gadolinium-based contrast agents into the body during some MRI exams. To address some of the anxiety and concerns over this issue, Paul Jannetto, Ph.D., DABCC, FAACC, and Joshua Bornhorst, Ph.D., DABCC, FAACC, Co-Directors of the Mayo Clinic Metals Laboratory and leading experts in this field, have compiled the following list of the most up-to-date information.

By Chris J. Bahnsen • February 27, 2018

The National Kidney Foundation, the American Society for Clinical Pathology, and the nation’s leading laboratories and clinical laboratory societies have announced a new collaboration to remove barriers to testing for chronic kidney disease.

By Gina Chiri-Osmond • February 27, 2018

A team of Mayo Clinic pathologists have discovered a new tissue biomarker, DNAJB9, for fibrillary glomerulonephritis, a rare kidney disease of unknown pathogenesis and poor outlook—nearly half of all patients end up on dialysis within four years of diagnosis.

By Chris J. Bahnsen • October 17, 2017